Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -3.18 is 826% below its 5-year average of 0.44, near the low end of its 5-year range (-10.78–45.74).
As of the fiscal period ended Tuesday, June 30, 2026. 2.24% below its 12-month average of -3.11.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -3.18.
DEBT TO EQUITY RATIO
-3.18
DEBT TO EQUITY RATIO AVG TTM
-3.11
DEBT TO EQUITY RATIO AVG 3Y
1.44
DEBT TO EQUITY RATIO AVG 5Y
0.44
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-2.24%
CURRENT VS 3Y AVG
-320.68%
CURRENT VS 5Y AVG
-825.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 773 covered companies
CURRENT VS SECTOR MEDIAN
-2992.65%
vs the sector median at left
Vivos Therapeutics, Inc.
Market Cap
$2.14M
Debt to Equity Ratio
-3.18
TTM Avg
-3.11
3Y Avg
1.44
5Y Avg
0.44
Market Cap
$2.32M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$2.37M
Debt to Equity Ratio
0.32
TTM Avg
2.13
3Y Avg
1.88
5Y Avg
1.88
Market Cap
$2.38M
Debt to Equity Ratio
0.01
TTM Avg
0.88
3Y Avg
0.53
5Y Avg
0.53
Market Cap
$2.38M
Debt to Equity Ratio
0.03
TTM Avg
0.05
3Y Avg
0.03
5Y Avg
0.02
Market Cap
$1.88M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$1.88M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.09
5Y Avg
0.07
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vivos Therapeutics, Inc. (VVOS) | $2.14M | -3.18 | -3.11 | 1.44 | 0.44 |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | 0.18 | 0.11 | 0.06 | 0.04 |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | 0.00 | 0.00 | 0.00 | 0.00 |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | 0.32 | 2.13 | 1.88 | 1.88 |
| Onconetix, Inc. (ONCO)vs › | $2.37M | 0.01 | 0.49 | 0.33 | 0.20 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | 0.01 | 0.88 | 0.53 | 0.53 |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | 0.03 | 0.05 | 0.03 | 0.02 |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | 0.00 | 0.00 | 0.03 | 0.03 |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.88M | 0.00 | 0.00 | 0.09 | 0.07 |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | N/A | 0.05 | 0.66 | 0.66 |
Debt/Equity
-3.18
Current Ratio
0.21
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -3.18 |
| 2026-03-31 | -10.78 |
| 2025-12-31 | -9.06 |
| 2025-09-30 | 4.94 |
| 2025-06-30 | 2.53 |
| 2025-03-31 | 0.32 |
| 2024-12-31 | 0.19 |
| 2024-09-30 | 0.21 |
| 2024-06-30 | 0.28 |
| 2024-03-31 | 3.23 |
| 2023-12-31 | 4.85 |
| 2023-09-30 | 45.74 |
| 2023-06-30 | 1.05 |
| 2023-03-31 | 0.33 |
| 2022-12-31 | 0.50 |
| 2022-09-30 | 0.29 |
| 2022-06-30 | 0.20 |
| 2022-03-31 | 0.11 |
| 2021-12-31 | 0.06 |
| 2021-09-30 | 0.04 |
| 2021-06-30 | 0.03 |
| 2021-03-31 | 0.09 |
| 2020-12-31 | 0.08 |
| 2020-09-30 | -0.72 |
| 2020-06-30 | -0.66 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | -1.26 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
